Diary

Description: In this course I describe the faulty genes, pathways and proteins that drive small cell and non-small cell lung cancer. I also explain the scientific rationale behind targeted treatments in use and in development for these diseases, such as EGFR inhibitors, ALK and ROS1 inhibitors, B-Raf inhibitors, angiogenesis inhibitors and immunotherapy with checkpoint inhibitors.
Level: Intermediate/Advanced
Audience: Ideal for pharmacists, research nurses, people from pharmaceutical companies, junior doctors or anyone who has been on one of my other courses. Requires a basic understanding of cancer genetics and cancer cell biology.
Cost: TBC
To book, contact: conferenceteam@rmh.nhs.uk or call: 020 7808 2922
View an outline of the programme

Description: In this course I describe the faulty genes, pathways and proteins that drive colorectal, head and neck, pancreatic, oesophageal, gastric and primary liver cancer. I also explain the science behind many targeted treatment approaches for these diseases, including EGFR- and HER2-targeted antibodies, angiogenesis inhibitors and immunotherapy with checkpoint inhibitors.
Level: Intermediate/Advanced
Audience: Ideal for pharmacists, research nurses, people from pharmaceutical companies, junior doctors or anyone who has been on one of my other courses. Requires a basic understanding of cancer genetics and cancer cell biology.
Cost: TBC
To book, contact: conferenceteam@rmh.nhs.uk or call: 020 7808 2922
View an outline of the programme

Description: A half-day course repeated morning and afternoon describing the theory behind the new immunotherapy treatments for cancer such as checkpoint inhibitors (ipilimumab, pembrolizumab, nivolumab, atezolizumab, durvalumab), adoptive cell transfer (CAR T cell therapy, infiltrating T cells), and vaccine-based treatments (peptide and DNA vaccines, oncolytic viruses, dendritic cell vaccines).
Level: Intermediate
Audience: Ideal for anyone with an A level or equivalent understanding of cell biology and genetics and who works with cancer patients, data or treatments.
To book, contact: conferenceteam@rmh.nhs.uk or call: 020 7808 2922
View an outline of the programme

Description: Using a combination of colourful diagrams and clear explanations, I will describe the gene mutations and other defects that drive ovarian cancer (including fallopian tube and other primary peritoneal cancers). I will also examine how this knowledge impacts treatment choice and explain the science behind chemotherapy and PARP, B-Raf and angiogenesis inhibitors. The day will also include the potential of immunotherapy and novel approaches for treatment, screening and patient monitoring.
Level: Intermediate
Audience: Ideal for anyone with an A level or equivalent understanding of cell biology and genetics and who works with cancer patients, data or treatments.
Cost: TBC
To book, contact: conferenceteam@rmh.nhs.uk or call: 020 7808 2922
View an outline of the programme

Description: In this study day I describe the unique cellular and genetic features of haematological cancers and covers a diverse range of targeted treatments for leukaemias, lymphomas and multiple myeloma. Treatments explained include a wide range of monoclonal antibodies, B cell receptor signalling blockers and JAK2, Bcl-2, FLT3 and CDK inhibitors. I also explore the potential of immunotherapy with checkpoint inhibitors and CAR T cells.
Level: Intermediate/Advanced
Audience:Ideal for pharmacists, research nurses, people from pharmaceutical companies, junior doctors or anyone who has been on one of my other courses. Requires a basic understanding of cancer genetics and cancer cell biology.
Cost: TBC
To book, contact: conferenceteam@rmh.nhs.uk or call: 020 7808 2922
View an outline of the programme

This study day is being organised by Amgen.
Elaine will deliver the morning session, covering:

Part 1:
The cellular and genetic make-up of acute lymphoblastic leukaemia (ALL)
• A bit about B cells
• Genetic drivers of ALL
• Clonal evolution & intratumoural heterogeneity
• The role of leukaemic stem cells

Treating Philadelphia Chromosome Positive ALL
• Bcr-Abl inhibitors
• Other treatments

Part 2:
Licensed and novel treatments for ALL
• Blinatumumab
• Inotuzumab ozogamicin
• CAR-modified T cells
• Other treatments in trials

Contact Elaine if you would like to know how to book a place.

View the programme

Elaine will be delivering a plenary session at 9:15am Sunday morning:

Cancer immunotherapy: what’s all the fuss about?

View the full programme

For those of you attending this year's NCRI conference in Glasgow, I will be running workshops on Monday and Tuesday morning to explain and unravel the scientific content of each day's programme.

My workshops are for people who plan to attend the day's lectures whilst fearing that they won’t understand the relevant scientific concepts.

My workshops will be tailored according to the topics of the plenary sessions at this year's conference.

Similar to previous years’ workshops, I will use diagrams and illustrations to provide clear, easy-to-understand explanations of complicated biological concepts.

The workshops are geared towards non-scientists, such as doctors, nurses, trials staff and patients who’d like to get the most out of this year’s conference.

View the full conference programme

Description: 1-day course covering a wide range of licensed and experimental cancer treatments, explaining their mechanism of action at a molecular and cellular level. Treatments described include: growth factor receptor inhibitors, kinase inhibitors, monoclonal antibodies, PARP inhibitors, ALK inhibitors, CDK inhibitors, immunotherapies.
Level: Advanced
Audience: Ideal for pharmacists, research nurses, pharmaceutical companies, junior doctors or anyone who has been on one of Elaine’s other courses
Cost: £150
To book, contact: conferenceteam@rmh.nhs.uk
View an outline of the programme